通过高档抗生素的疗效成本比分析及不良反应观察 ,指导临床合理用药。方法　 5 0例感染病人分成三组 ,前瞻性比较亚胺培南组、三代头孢组及混合用药组病人的疗效、成本、细菌清除率和真菌病的发生率。结果　三组在疗效、细菌清除率和真菌病的发生率方面无显著差别。混合用药组的观察药物费用和总费用高于亚胺培南组和三代头孢组。结论　亚胺培南和三代头孢具有相似的疗效成本比 ,应尽量避免三代头孢和亚胺培南先后应用在同一个感染病人 By high-grade antibiotic efficacy and cost-benefit analysis of adverse reactions, to guide clinical rational use of drugs. Methods Fifty patients with infection were divided into three groups. Prospectively compare the curative effect, cost, bacterial clearance rate and mycosis incidence among patients in imipenem group, third generation cephalosporin group and mixed drug group. Results There was no significant difference in efficacy, bacterial clearance and incidence of mycosis between the three groups. The observed drug cost and the total cost of the mixed drug group were higher than those of the imipenem group and the third generation cephalosporin group. Conclusion imipenem and third-generation cephalosporin have a similar cost-effectiveness ratio should be avoided third-generation cephalosporins and imipenem have been used in the same infected patients